Business Desk :
A nationwide diabetes patient registry will be introduced in Bangladesh electronically with a view to delivering quality care for patient living with diabetes through analysing epidemiology and treatment outcomes. The electronic registry will be implemented through the institutions of Diabetic Association of Bangladesh (BADAS) and its affiliated associations across the country with the support of Novo Nordisk.
The first of its kinds, BADAS President Prof. A.K Azad Khan and Novo Nordisk’s Senior Vice President Frederik Kier signed an agreement on Sunday to develop the registry.
“In Bangladesh there is no conclusive study or survey which provides an exact number or figure of the diabetic population”, said Prof. Azad Khan. “The new nationwide registry will generate data on patient numbers, blood glucose level before and after meal, three-month average of glucose in blood (HbA1c), renal and cardiac history of patients living with diabetes and other relevance. Quality care will be ensured though analysing these data,” he said.
Improving the understanding of diabetes and the need for its prevention is critical, which is why Novo Nordisk works to raise awareness for the diabetes epidemic and its impact in Bangladesh, said Frederick Kier. As a global leader in diabetes care, Novo Nordisk has a responsibility to work for improving understanding of diabetes and the need for its prevention, he said.
A nationwide diabetes patient registry will be introduced in Bangladesh electronically with a view to delivering quality care for patient living with diabetes through analysing epidemiology and treatment outcomes. The electronic registry will be implemented through the institutions of Diabetic Association of Bangladesh (BADAS) and its affiliated associations across the country with the support of Novo Nordisk.
The first of its kinds, BADAS President Prof. A.K Azad Khan and Novo Nordisk’s Senior Vice President Frederik Kier signed an agreement on Sunday to develop the registry.
“In Bangladesh there is no conclusive study or survey which provides an exact number or figure of the diabetic population”, said Prof. Azad Khan. “The new nationwide registry will generate data on patient numbers, blood glucose level before and after meal, three-month average of glucose in blood (HbA1c), renal and cardiac history of patients living with diabetes and other relevance. Quality care will be ensured though analysing these data,” he said.
Improving the understanding of diabetes and the need for its prevention is critical, which is why Novo Nordisk works to raise awareness for the diabetes epidemic and its impact in Bangladesh, said Frederick Kier. As a global leader in diabetes care, Novo Nordisk has a responsibility to work for improving understanding of diabetes and the need for its prevention, he said.
